News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
168,378 Results
Type
Article (6773)
Company Profile (110)
Press Release (161495)
Section
Business (53817)
Career Advice (354)
Deals (9764)
Drug Delivery (30)
Drug Development (31961)
Employer Resources (68)
FDA (2724)
Job Trends (4136)
News (96493)
Policy (6751)
Tag
Academia (255)
Alliances (12261)
Alzheimer's disease (374)
Antibody-drug conjugate (ADC) (44)
Approvals (2737)
Artificial intelligence (61)
Bankruptcy (63)
Best Places to Work (3219)
Biotechnology (72)
Breast cancer (48)
Cancer (524)
Career advice (301)
CAR-T (45)
Cell therapy (114)
Clinical research (26860)
Collaboration (229)
Compensation (206)
COVID-19 (649)
C-suite (76)
Data (594)
Diabetes (51)
Diagnostics (599)
Earnings (22748)
Employer resources (59)
Events (33524)
Executive appointments (250)
FDA (2985)
Funding (168)
Gene therapy (59)
GLP-1 (231)
Government (717)
Healthcare (2299)
Infectious disease (673)
Inflammatory bowel disease (44)
Interviews (57)
IPO (5761)
Job creations (1024)
Job search strategy (259)
Layoffs (122)
Legal (907)
Lung cancer (89)
Manufacturing (94)
Medical device (442)
Medtech (443)
Mergers & acquisitions (4192)
Metabolic disorders (184)
Neuroscience (514)
NextGen: Class of 2025 (978)
Non-profit (238)
Northern California (876)
Obesity (96)
Opinion (75)
Patents (53)
People (17119)
Phase I (8130)
Phase II (12384)
Phase III (9019)
Pipeline (301)
Policy (49)
Postmarket research (510)
Preclinical (3022)
Radiopharmaceuticals (109)
Rare diseases (86)
Real estate (1199)
Regulatory (5619)
Research institute (282)
Southern California (685)
Startups (957)
United States (6575)
Vaccines (143)
Weight loss (53)
Date
Last 7 days (223)
Last 30 days (825)
Last 365 days (12285)
2025 (1554)
2024 (12551)
2023 (14350)
2022 (16213)
2021 (17844)
2020 (15215)
2019 (10003)
2018 (7149)
2017 (8948)
2016 (7308)
2015 (9302)
2014 (7062)
2013 (5085)
2012 (4915)
2011 (4844)
2010 (4810)
Location
Africa (165)
Asia (13423)
Australia (1465)
California (1820)
Canada (449)
China (243)
Colorado (66)
Connecticut (78)
Delaware (61)
Europe (24309)
Florida (223)
Georgia (53)
Illinois (87)
Indiana (65)
Japan (49)
Kansas (48)
Maryland (200)
Massachusetts (1457)
Minnesota (64)
New Jersey (656)
New York (621)
North Carolina (319)
Northern California (876)
Ohio (60)
Pennsylvania (329)
South America (209)
Southern California (685)
Texas (187)
Washington State (129)
168,378 Results for "enochian biopharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Bankruptcy
Biopharma Bankruptcies Still At Peak, With Little Relief in Sight
2023 marked the most bankruptcies in biopharma in more than a decade, with 14 companies filing for Chapter 11 protection. The number remained high in 2024.
February 19, 2025
·
5 min read
·
Annalee Armstrong
NextGen
BioSpace
’s NextGen Class of 2025 Leans Into Biopharma’s Hottest Trends
From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.
January 7, 2025
·
5 min read
·
Heather McKenzie
Career Advice
The Top 12 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the
BioSpace
list of 12 top companies hiring life sciences professionals like you.
February 6, 2025
·
1 min read
·
Angela Gabriel
Collaboration
The Top 7 Biopharma Licensing Deals of 2024
Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their pipelines with novel and potentially more effective therapies.
February 5, 2025
·
8 min read
·
Tristan Manalac
FDA
FDA Reels From ‘Indiscriminate’ Job Cuts Under Trump as Biopharma Appeals for Clarity
Morale is low at the FDA, which was hit with layoffs this week following RFK Jr.’s confirmation. Biopharma leaders and agency insiders fear further workforce cuts could delay new medicines.
February 20, 2025
·
5 min read
·
Heather McKenzie
Deals
The Biopharma Crystal Ball Comes Out at JPM25
Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea for the slow, healthy recovery of the industry at large.
January 17, 2025
·
3 min read
·
Annalee Armstrong
Manufacturing
Biopharma’s Big Question of 2024: Can You Scale It?
Suddenly the hottest thing in biopharma isn’t a new indication, disease target or modality—it’s manufacturing, and all of pharma is going to be vying for capacity and talent.
December 18, 2024
·
5 min read
·
Annalee Armstrong
Venture capitalists
The Megaround Ruled Biopharma in 2024 as First-Time VC Funding Doubled
Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 deals in 2023.
January 9, 2025
·
2 min read
·
Annalee Armstrong
Layoffs
Layoffs Continued Across Biopharma in 2024
While layoffs slowed in the second half of 2024, biopharmas including Bayer, Bristol Myers Squibb and Johnson & Johnson cut hundreds or even thousands of employees over the course of the year.
December 31, 2024
·
130 min read
·
BioSpace Editorial Staff
Government
WHO Withdrawal, CGT Access, IRA: Trump’s Initial Policies Raise Questions for Biopharma
At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, President Trump issued multiple executive orders that concern the industry.
January 22, 2025
·
5 min read
·
Annalee Armstrong
1 of 16,838
Next
